Study identifier:D1531C00012
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A Phase I Open, Non-randomised, Single-centre Study to Assess the Metabolism, Excretion and Pharmacokinetics of AZD1152 and AZD1152 hQPA Following Intravenous Administration of [14C]-AZD1152 in Patients With Acute Myeloid Leukaemia (AML)
Acute Myeloid Leukaemia
Phase 1
No
AZD1152, C14 AZD1152
All
5
Interventional
18 Years +
Allocation: Non-randomized
Endpoint Classification: Pharmacokinetics/dynamics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
The purpose of the study is to assess how AZD1152 is absorbed or excreted in and out of the body in patients with Acute Myeloid Leukaemia (AML).
Location
Location
Manchester, United Kingdom
Arms | Assigned Interventions |
---|---|
Experimental: AZD1152 100 mg Lyophile 5 mL Diluent | Drug: AZD1152 100mg Lyophile, 5mL Diluent IV infusion |
Experimental: C14 AZD1152 AZD1152 radiolabelled IV solution. 1.05 mg/ml will be presented as a 15 ml fill in a 20 ml vial. | Drug: C14 AZD1152 radiolabelled IV solution, 1.05 mg/ml presented as 15 ml fill in 20ml vial infusion |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.